

Christopher E M Griffiths

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/177599/publications.pdf>

Version: 2024-02-01

728
papers

53,819
citations

1163

111
h-index

2375

198
g-index

756
all docs

756
docs citations

756
times ranked

27745
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1482-1490.	1.1	6
2	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2022, 33, 848-856.	1.1	25
3	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)*. <i>British Journal of Dermatology</i> , 2022, 186, 245-256.	1.4	22
4	Restoration of collagen and elastic fibre networks following treatment of photoaged skin with SerAnesse, a novel over-the-counter anti-ageing product. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, e43.	1.3	0
5	Physical activity is important for cardiovascular health and cardiorespiratory fitness in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 289-296.	0.6	2
6	Can Skin Aging Contribute to Systemic Inflammation?. <i>Journal of Investigative Dermatology</i> , 2022, 142, 484-485.	0.3	1
7	Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1617-1628.e10.	0.3	11
8	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	1.4	6
9	How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast). <i>British Journal of Dermatology</i> , 2022, , .	1.4	2
10	Paradoxical eczema in patients with psoriasis receiving biologics: a case series. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1174-1178.	0.6	8
11	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	1.4	9
12	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
13	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-240.	0.4	0
14	Influence of menopause and hormone replacement therapy on epidermal ageing and skin biomechanical function. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	4
15	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-106.	0.9	1
16	A rapid access clinic for psoriasis: first experiences. <i>British Journal of Dermatology</i> , 2022, 187, 426-428.	1.4	2
17	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 882-893.	1.5	21
18	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2022, 12, 1431-1446.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Secukinumab improves the quality of life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open-label study (SIGNATURE). <i>Journal of Dermatology</i> , 2022, 1, 207-218.		0
20	Reduced cutaneous CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to skin. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
21	Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC ^Â) clinical information system from 2010 to 2020. <i>British Journal of Dermatology</i> , 2022, 187, 713-721.	1.4	3
22	Multifaceted amelioration of cutaneous photoageing by (0.3%) retinol. <i>International Journal of Cosmetic Science</i> , 2022, 44, 625-635.	1.2	5
23	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 123-134.	1.3	25
24	Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink*. <i>British Journal of Dermatology</i> , 2021, 184, 78-86.	1.4	26
25	Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*. <i>British Journal of Dermatology</i> , 2021, 184, 243-258.	1.4	65
26	Diurnal and seasonal variation in psoriasis symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e45-e47.	1.3	22
27	An evaluation of dermatology patients shielding during the COVID-19 outbreak. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 193-194.	0.6	4
28	Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 276-285.	0.6	4
29	Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 928-937.	1.3	2
30	Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
31	Distinctive clinical and histological characteristics of atrophic and hypertrophic facial photoageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 762-768.	1.3	17
32	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058.	1.4	58
33	Implementation of the PsoWell ^Â Model for the Management of People with Complex Psoriasis. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00445.	0.6	8
34	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
35	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e498-e501.	1.3	2
36	Predicting Proteolysis in Complex Proteomes Using Deep Learning. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3071.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Inflammaging and the Skin. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1087-1095.	0.3	87
38	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. <i>British Journal of Dermatology</i> , 2021, 185, 935-944.	1.4	30
39	Psoriasis. <i>Lancet, The</i> , 2021, 397, 1301-1315.	6.3	792
40	Peptide location fingerprinting reveals modification-associated biomarker candidates of ageing in human tissue proteomes. <i>Aging Cell</i> , 2021, 20, e13355.	3.0	9
41	AB0532...MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1297-1298.	0.5	2
42	Immediate global support is needed for Myanmar. <i>British Journal of Dermatology</i> , 2021, 185, 466-467.	1.4	1
43	Development of clinical diagnostic criteria for chronic plaque psoriasis: an international eDelphi study. <i>British Journal of Dermatology</i> , 2021, 185, 455-456.	1.4	3
44	AB0528...COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1293-1294.	0.5	1
45	Professor Lionel Fry (1933-2021). <i>British Journal of Dermatology</i> , 2021, 185, 237-238.	1.4	0
46	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	0.8	9
47	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e496-e498.	1.3	4
48	Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. <i>British Journal of Dermatology</i> , 2021, 185, 441-443.	1.4	13
49	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021, 185, 825-835.	1.4	4
50	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	1.4	19
51	The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1262-1269.	0.6	6
52	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.4	30
53	Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. <i>British Journal of Dermatology</i> , 2021, 185, 978-987.	1.4	4
54	Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study. <i>PLoS ONE</i> , 2021, 16, e0254661.	1.1	3

#	ARTICLE	IF	CITATIONS
55	The art of observation: visual literacy for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e809-e811.	1.3	4
56	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.4	21
57	The promise and challenges of cell therapy for psoriasis*. <i>British Journal of Dermatology</i> , 2021, 185, 887-898.	1.4	13
58	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2409-2414.	1.3	6
59	Tender facial nodules in a man receiving adalimumab for psoriasis. <i>Clinical and Experimental Dermatology</i> , 2021, , .	0.6	0
60	Psoriasis Prevalence in Adults in the United States. <i>JAMA Dermatology</i> , 2021, 157, 940.	2.0	165
61	Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 185, 952-960.	1.4	5
62	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1872-1878.	0.3	4
63	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	1.3	18
64	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	5.8	23
65	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.4	36
66	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	1.1	3
67	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. <i>JAMA Dermatology</i> , 2021, 157, 66.	2.0	14
68	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
69	Does the lifestyle of patients with psoriasis affect their illness?. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 643-654.	0.1	0
70	Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. <i>British Journal of Dermatology</i> , 2020, 183, 128-138.	1.4	46
71	Secukinumab for patients failing previous tumour necrosis factor- α inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020, 183, 60-70.	1.4	21
72	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 769-778.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Basal cell carcinoma genetic susceptibility increases the rate of skin ageing: a Mendelian randomization study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 97-100.	1.3	8
74	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register). <i>Journal of Investigative Dermatology</i> , 2020, 140, S145-S146.	0.3	0
75	Genetic interaction between placental growth factor and vascular endothelial growth factor A in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 302-308.	0.6	6
76	Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting. <i>Dermatologic Therapy</i> , 2020, 33, e13166.	0.8	6
77	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
78	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	1.4	51
79	The short-term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients. <i>Dermatologic Therapy</i> , 2020, 33, e13179.	0.8	4
80	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020, 107, 539-543.	2.6	44
81	Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 1160-1167.	1.6	4
82	Celebrating the 50th Anniversary of ESDR. <i>Journal of Investigative Dermatology</i> , 2020, 140, S189-S190.	0.3	2
83	The Skin Science Foundation: Promoting Skin Health through Research. <i>Journal of Investigative Dermatology</i> , 2020, 140, S189-S190.	0.3	2
84	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	2.0	18
85	The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. <i>British Journal of Dermatology</i> , 2020, 183, 981-983.	1.4	2
86	The Future of ESDR. <i>Journal of Investigative Dermatology</i> , 2020, 140, S192-S193.	0.3	0
87	The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology. <i>Sleep Medicine</i> , 2020, 72, 144-149.	0.8	7
88	The systemic influence of chronic smoking on skin structure and mechanical function. <i>Journal of Pathology</i> , 2020, 251, 420-428.	2.1	13
89	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	0.6	48
90	National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. <i>BMJ</i> , 2020, 369, m1590.	3.0	479

#	ARTICLE	IF	CITATIONS
91	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 792-794.	1.4	58
92	“Mind the gap”: what patients and clinicians believe is “unknown” about psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 399-400.	1.4	1
93	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020, 183, 294-302.	1.4	85
94	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
95	Heterogeneity of fibrillin-rich microfibrils extracted from human skin of diverse ethnicity. <i>Journal of Anatomy</i> , 2020, 237, 478-486.	0.9	8
96	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 619-626.	3.3	9
97	What are the barriers to physical activity in patients with chronic plaque psoriasis?*. <i>British Journal of Dermatology</i> , 2020, 183, 1094-1102.	1.4	16
98	The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision-making tools in psoriasis?. <i>Dermatologic Therapy</i> , 2020, 33, e13276.	0.8	8
99	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020, 13, 400-409.	1.5	9
100	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1440-1448.	1.3	47
101	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.4	18
102	Proteomic fingerprints of damage in extracellular matrix assemblies. <i>Matrix Biology Plus</i> , 2020, 5, 100027.	1.9	19
103	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.3	6
104	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020, 21, 158.	0.7	7
105	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2019, 180, 329-337.	1.4	36
106	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	1.5	165
107	Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 108-115.	1.4	34
108	Incidence and prevalence of psoriasis in Israel between 2011 and 2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2075-2081.	1.3	29

#	ARTICLE	IF	CITATIONS
109	Association of Psoriasis With the Risk of Developing or Dying of Cancer. <i>JAMA Dermatology</i> , 2019, 155, 1390.	2.0	89
110	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	2.0	30
111	Mass spectrometry-based proteomics reveals the distinct nature of the skin proteomes of photoaged compared to intrinsically aged skin. <i>International Journal of Cosmetic Science</i> , 2019, 41, 118-131.	1.2	10
112	Understanding the experience of sleep disturbance in psoriasis: a qualitative exploration using the Common-Sense Model of Self-Regulation. <i>British Journal of Dermatology</i> , 2019, 180, 1397-1404.	1.4	10
113	How does the International League of Dermatological Societies promote skin health for the world?. <i>British Journal of Dermatology</i> , 2019, 180, 1281-1283.	1.4	1
114	Ageing significantly impacts the biomechanical function and structural composition of skin. <i>Experimental Dermatology</i> , 2019, 28, 981-984.	1.4	39
115	The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2019, 181, 871-873.	1.4	15
116	An art-based visual literacy training course to enhance clinical skills in dermatology trainees. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e310-e312.	1.3	11
117	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.4	15
118	Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience. <i>British Journal of Dermatology</i> , 2019, 181, 599-601.	1.4	4
119	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	1.5	128
120	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 1069-1076.	1.4	74
121	Selective proteolysis by matrix metalloproteinases of photo-oxidised dermal extracellular matrix proteins. <i>Cellular Signalling</i> , 2019, 54, 191-199.	1.7	29
122	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.3	60
123	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019, 180, 894-901.	1.4	12
124	Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2019, 180, 1348-1351.	1.4	9
125	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019, 181, 256-264.	1.4	14
126	Aging in Skin of Color: Disruption to Elastic Fiber Organization Is Detrimental to Skin's Biomechanical Function. <i>Journal of Investigative Dermatology</i> , 2019, 139, 779-788.	0.3	42

#	ARTICLE	IF	CITATIONS
127	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	0.6	77
128	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 100-107.	0.3	30
129	Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres. <i>British Journal of Dermatology</i> , 2019, 180, 849-858.	1.4	33
130	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized <sc>VOYAGE</sc> 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1515-1522.	1.3	19
131	Lipidomics for translational skin research: A primer for the uninitiated. <i>Experimental Dermatology</i> , 2018, 27, 721-728.	1.4	23
132	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	0.6	163
133	Structural and compositional diversity of fibrillin microfibrils in human tissues. <i>Journal of Biological Chemistry</i> , 2018, 293, 5117-5133.	1.6	54
134	Defining tissue proteomes by systematic literature review. <i>Scientific Reports</i> , 2018, 8, 546.	1.6	11
135	Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication. <i>Psychology, Health and Medicine</i> , 2018, 23, 763-778.	1.3	31
136	A photonumeric scale for the assessment of atrophic facial photodamage. <i>British Journal of Dermatology</i> , 2018, 178, 1190-1195.	1.4	16
137	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 775-784.	0.3	71
138	Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. <i>Value in Health</i> , 2018, 21, 1010-1018.	0.1	16
139	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. <i>British Journal of Dermatology</i> , 2018, 179, 173-181.	1.4	64
140	Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. <i>British Journal of Dermatology</i> , 2018, 179, 863-871.	1.4	19
141	Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. <i>British Journal of Dermatology</i> , 2018, 178, 1297-1307.	1.4	8
142	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018, 154, 581.	2.0	74
143	Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1523-1529.	1.3	24
144	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 534-541.	0.3	62

#	ARTICLE	IF	CITATIONS
145	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. British Journal of Dermatology, 2018, 178, 1020-1027.	1.4	54
146	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 420-427.	1.3	70
147	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 2018, 178, 674-681.	1.4	80
148	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. British Journal of Dermatology, 2018, 178, 132-139.	1.4	57
149	Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership. British Journal of Dermatology, 2018, 178, 1383-1387.	1.4	4
150	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 2018, 138, 785-794.	0.3	48
151	Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17. British Journal of Dermatology, 2018, 178, 1364-1372.	1.4	24
152	Lower levels of interleukin-17 gene expression are associated with impaired Langerhans cell migration in aged human skin. Immunology, 2018, 153, 60-70.	2.0	29
153	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. European Journal of Dermatology, 2018, 28, 356-363.	0.3	18
154	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	0.7	15
155	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. Clinical and Experimental Dermatology, 2018, 43, 759-765.	0.6	5
156	Langerhans cells express human Î²-defensin 3: relevance for immunity during skin ageing. British Journal of Dermatology, 2018, 179, 1170-1171.	1.4	15
157	Keratinocytes derived from late-onset-psoriasis skin do not impair Langerhans cell migration. British Journal of Dermatology, 2018, 179, 1208-1209.	1.4	2
158	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. JAMA Dermatology, 2018, 154, 676.	2.0	90
159	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. Journal of Drugs in Dermatology, 2018, 17, 826-832.	0.4	31
160	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology, 2017, 76, 405-417.	0.6	673
161	Organization of the dermal matrix impacts the biomechanical properties of skin. British Journal of Dermatology, 2017, 177, 818-827.	1.4	50
162	Psoriasis and Atopic Dermatitis. Dermatology and Therapy, 2017, 7, 31-41.	1.4	60

#	ARTICLE	IF	CITATIONS
163	Functional magnetic resonance imaging in dermatology: The skin, the brain and the invisible. <i>Experimental Dermatology</i> , 2017, 26, 845-853.	1.4	27
164	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	3.3	29
165	“New to me”™: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well [®] patient materials mixed-methods feasibility study. <i>British Journal of Dermatology</i> , 2017, 177, 758-770.	1.4	25
166	The challenges of assessing patients' medication beliefs: a qualitative study. <i>BMC Health Services Research</i> , 2017, 17, 119.	0.9	13
167	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	6.3	884
168	The global state of psoriasis disease epidemiology: a workshop report. <i>British Journal of Dermatology</i> , 2017, 177, e4-e7.	1.4	109
169	The association between psoriasis and coeliac disease. <i>British Journal of Dermatology</i> , 2017, 177, e329-e330.	1.4	13
170	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1410-1421.	1.4	24
171	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017, 177, 828-836.	1.4	18
172	Systems medicine and psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 560-562.	1.4	2
173	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017, 177, 587-590.	1.4	10
174	A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1052-1059.	1.4	44
175	Treatment patterns and outcomes among adults admitted to hospital in the U.K. due to plaque or erythrodermic psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, e52-e54.	1.4	1
176	Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 260-267.	4.0	77
177	Reply to “Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials”™: reply from the authors. <i>British Journal of Dermatology</i> , 2017, 177, 1766-1767.	1.4	2
178	Alcohol-Related Mortality in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1256.	2.0	36
179	Inhibition of IL-17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections. <i>Clinical and Translational Immunology</i> , 2017, 6, e152.	1.7	67
180	A new in vitro assay to test UVR protection of dermal extracellular matrix components by a flat spectrum sunscreen. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 175, 58-64.	1.7	9

#	ARTICLE	IF	CITATIONS
181	Medication non-adherence: the hidden problem in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 923-924.	1.3	1
182	Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 323-332.	1.3	21
183	Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well study. <i>British Journal of Dermatology</i> , 2017, 176, 677-686.	1.4	39
184	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
185	Lysyl oxidase activity in human skin is increased by chronic ultraviolet radiation exposure and smoking. <i>British Journal of Dermatology</i> , 2017, 176, 1376-1378.	1.4	10
186	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901.	1.4	107
187	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-CABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 119-126.	1.3	92
188	Novel approaches to characterize age-related remodelling of the dermal-epidermal junction in 2D, 3D and <i>in vivo</i> . <i>Skin Research and Technology</i> , 2017, 23, 131-148.	0.8	29
189	Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. <i>British Journal of Dermatology</i> , 2017, 176, 650-658.	1.4	165
190	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.4	50
191	Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 667-676.	1.4	40
192	A visual literacy course for dermatology trainees. <i>British Journal of Dermatology</i> , 2017, 177, 310-311.	1.4	12
193	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	1.4	41
194	Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and Structure. <i>Acta Dermato-Venereologica</i> , 2016, 96, 641-644.	0.6	18
195	Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. <i>British Journal of Dermatology</i> , 2016, 174, 985-995.	1.4	65
196	Brain inflammation and psoriasis: a [¹¹ C]-(<i>R</i>)-PK11195 positron emission tomography study. <i>British Journal of Dermatology</i> , 2016, 175, 1082-1084.	1.4	14
197	THU0187...Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 253.1-253.	0.5	0
198	Age-Associated Skin Conditions and Diseases: Current Perspectives and Future Options. <i>Gerontologist</i> , The, 2016, 56, S230-S242.	2.3	146

#	ARTICLE	IF	CITATIONS
199	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	0.6	264
200	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.3	63
201	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. <i>British Journal of Dermatology</i> , 2016, 175, 1038-1044.	1.4	33
202	The role of personal models in clinical management: Exploring health care providers' beliefs about psoriasis. <i>British Journal of Health Psychology</i> , 2016, 21, 114-134.	1.9	15
203	The risk of postoperative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 86-91.	1.3	24
204	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016, 174, 212-215.	1.4	6
205	The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions. <i>British Journal of Dermatology</i> , 2016, 174, 1351-1358.	1.4	46
206	Interleukin-17 and interleukin-23 regulate Langerhans cell migration. <i>British Journal of Dermatology</i> , 2016, 175, 622-624.	1.4	4
207	Primary care-based screening for cardiovascular risk factors in patients with psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 348-356.	1.4	26
208	Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 407-409.	0.6	5
209	Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 168-178.	0.8	9
210	A novel mutation in IL36RN underpins childhood pustular dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 302-305.	1.3	15
211	P16INK4a Positive Cells in Human Skin Are Indicative of Local Elastic Fiber Morphology, Facial Wrinkling, and Perceived Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1022-1028.	1.7	62
212	Interleukin 17-A inhibition in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1-4.	1.3	28
213	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016, 308, 201-205.	1.1	35
214	The impact of intrinsic ageing on the protein composition of the dermal-epidermal junction. <i>Mechanisms of Ageing and Development</i> , 2016, 156, 14-16.	2.2	69
215	I should have taken that further" missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed methods study. <i>Health Expectations</i> , 2016, 19, 1121-1137.	1.1	28
216	Ixekizumab for psoriasis " Authors' reply. <i>Lancet</i> , The, 2016, 387, 226-227.	6.3	3

#	ARTICLE	IF	CITATIONS
217	Novel systemic therapies for the treatment of psoriasis. Expert Opinion on Pharmacotherapy, 2016, 17, 79-92.	0.9	18
218	Measurement, Classification and Evaluation of Sleep Disturbance in Psoriasis: A Systematic Review. PLoS ONE, 2016, 11, e0157843.	1.1	44
219	Pilot study assessing pathophysiology and healing of digital ulcers in patients with systemic sclerosis using laser Doppler imaging and thermography. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 100-105.	0.4	9
220	The global challenge for skin health. British Journal of Dermatology, 2015, 172, 1469-1472.	1.4	50
221	Markers of health and disease and pigmented spots in a middle-aged population. British Journal of Dermatology, 2015, 173, 1550-1552.	1.4	8
222	A fresh look at T cells in psoriasis. British Journal of Dermatology, 2015, 173, 891-892.	1.4	0
223	Patient-reported outcome measures in psoriasis: the good, the bad and the missing!. British Journal of Dermatology, 2015, 172, 1210-1221.	1.4	48
224	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
225	Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. British Journal of Dermatology, 2015, 173, 1271-1273.	1.4	10
226	Interventions for photodamaged skin. The Cochrane Library, 2015, 2015, CD001782.	1.5	4
227	A pilot study examining mindfulness-based cognitive therapy in psoriasis. Psychology, Health and Medicine, 2015, 20, 121-127.	1.3	86
228	The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. British Journal of Dermatology, 2015, 172, 130-137.	1.4	69
229	A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissues. Redox Biology, 2015, 5, 101-113.	3.9	45
230	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
231	Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Molecular BioSystems, 2015, 11, 2198-2209.	2.9	20
232	Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology, 2015, 135, 2903-2907.	0.3	30
233	Over-the-counter anti-ageing topical agents and their ability to protect and repair photoaged skin. Maturitas, 2015, 80, 265-272.	1.0	20
234	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 468-473.	1.3	11

#	ARTICLE	IF	CITATIONS
235	Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. <i>British Journal of Dermatology</i> , 2015, 172, 230-238.	1.4	20
236	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. <i>Journal of Dermatological Treatment</i> , 2015, 26, 329-334.	1.1	11
237	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015, 172, 1395-1406.	1.4	127
238	A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented Spots. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1735-1742.	0.3	117
239	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> 73, 37-49.	0.6	498
240	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	1.1	50
241	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2964-2970.	0.3	89
242	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and) <i>Tj ETQq0 0.0 rgBT /Overlock</i> 719	0.3	719
243	A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children. <i>Journal of Dermatological Treatment</i> , 2015, 26, 291-296.	1.1	6
244	Disentangling the effects of circulating IGF-1, glucose, and cortisol on features of perceived age. <i>Age</i> , 2015, 37, 9771.	3.0	6
245	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2189-2197.	0.3	132
246	Acne conglobata and adalimumab: use of tumour necrosis factor- α antagonists in treatment-resistant acne conglobata, and review of the literature. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 383-386.	0.6	38
247	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
248	The acceptability and usefulness of mindfulness-based cognitive therapy for people living with psoriasis: a qualitative study. <i>British Journal of Dermatology</i> , 2015, 172, 823-825.	1.4	15
249	Lifestyle and youthful looks. <i>British Journal of Dermatology</i> , 2015, 172, 1338-1345.	1.4	23
250	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
251	Do English healthcare settings use "Choice Architecture" principles in promoting healthy lifestyles for people with psoriasis? An observational study. <i>BMC Health Services Research</i> , 2015, 15, 215.	0.9	8
252	Psoriasis treatment and management - a systematic review of full economic evaluations. <i>British Journal of Dermatology</i> , 2015, 172, 574-583.	1.4	12

#	ARTICLE	IF	CITATIONS
253	Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 161-166.	1.0	17
254	The International Psoriasis Council: Advancing Knowledge, Enhancing Care. <i>Dermatologic Clinics</i> , 2015, 33, ix-xii.	1.0	1
255	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 224-231.	1.3	31
256	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015, 172, 933-939.	1.4	17
257	“In someone's clinic but not in mine” – clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. <i>British Journal of Dermatology</i> , 2014, 171, 1116-1122.	1.4	30
258	Treatment-Related Restoration of Langerhans Cell Migration in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 268-271.	0.3	17
259	Responsiveness to Change and Interpretability of the Simplified Psoriasis Index. <i>Journal of Investigative Dermatology</i> , 2014, 134, 351-358.	0.3	32
260	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1459-1462.	0.3	26
261	Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration. <i>British Journal of Dermatology</i> , 2014, 171, 409-411.	1.4	11
262	Topical photodynamic therapy following excisional wounding of human skin increases production of transforming growth factor- β 23 and matrix metalloproteinases 1 and 9, with associated improvement in dermal matrix organization. <i>British Journal of Dermatology</i> , 2014, 171, 55-62.	1.4	33
263	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 206-209.	1.4	9
264	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. <i>British Journal of Dermatology</i> , 2014, 171, 485-491.	1.4	32
265	Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. <i>British Journal of Dermatology</i> , 2014, 171, 602-608.	1.4	14
266	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.5	25
267	A quasiqucentennial reflection on psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 231-233.	1.4	1
268	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	0.9	177
269	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 61-62.	1.1	1
270	Damage to Skin Extracellular Matrix Induced by UV Exposure. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 1063-1077.	2.5	116

#	ARTICLE	IF	CITATIONS
271	Geographical ancestry is a key determinant of epidermal morphology and dermal composition. <i>British Journal of Dermatology</i> , 2014, 171, 274-282.	1.4	29
272	Naevus sebaceus: a mosaic RASopathy. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 1-6.	0.6	51
273	Epicutaneous exposure to proteins and skin immune function. <i>European Journal of Dermatology</i> , 2014, 24, 10-14.	0.3	14
274	A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. <i>Rheumatology</i> , 2014, 53, 1422-1430.	0.9	25
275	Skin health in older age. <i>Maturitas</i> , 2014, 79, 256-264.	1.0	45
276	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014, 14, 47-53.	0.8	7
277	<i>In vitro</i> and <i>in vivo</i> studies with tetrahydrojasmonic acid (LR2412) reveal its potential to correct signs of skin ageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 415-423.	1.3	20
278	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	13.9	1,675
279	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	2.6	153
280	Scanning acoustic microscopy of biological cryosections: the effect of local thickness on apparent acoustic wave speed. <i>Materials Research Society Symposia Proceedings</i> , 2014, 1621, 143-148.	0.1	0
281	Expression of microRNA-184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013, 228, 2314-2323.	2.0	39
282	Does psychosocial stress play a role in the exacerbation of psoriasis?. <i>British Journal of Dermatology</i> , 2013, 169, 965-974.	1.4	82
283	Adherence to medication in patients with psoriasis: a systematic literature review. <i>British Journal of Dermatology</i> , 2013, 168, 20-31.	1.4	125
284	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. <i>British Journal of Dermatology</i> , 2013, 168, 864-866.	1.4	11
285	Cutaneous <i>Mycobacterium haemophilum</i> infection in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 446-447.	1.4	11
286	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013, 168, 374-380.	1.4	16
287	Recognition of need in health care consultations: a qualitative study of people with psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 354-361.	1.4	69
288	Challenges and approaches for the development of safer immunomodulatory biologics. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 306-324.	21.5	138

#	ARTICLE	IF	CITATIONS
289	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , 2013, 168, 844-854.	1.4	350
290	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1366-1369.	0.3	140
291	A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. <i>British Journal of Dermatology</i> , 2013, 169, 329-336.	1.4	64
292	Can stress reduction interventions improve psoriasis? A review. <i>Psychology, Health and Medicine</i> , 2013, 18, 501-514.	1.3	29
293	Cross-linking of structural proteins in ageing skin: an in situ assay for the detection of amine oxidase activity. <i>Biogerontology</i> , 2013, 14, 89-97.	2.0	23
294	A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 483-486.	0.6	47
295	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. <i>Journal of Investigative Dermatology</i> , 2013, 133, 377-385.	0.3	1,827
296	The Simplified Psoriasis Index (SPI): A Practical Tool for Assessing Psoriasis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1956-1962.	0.3	54
297	Dr. Murray, et al reply. <i>Journal of Rheumatology</i> , 2013, 40, 206.2-206.	1.0	1
298	Biologic therapies in dermatology. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 12-17.	0.2	0
299	Facial Appearance Reflects Human Familial Longevity and Cardiovascular Disease Risk in Healthy Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 145-152.	1.7	45
300	“On the surface”: a qualitative study of GPs’ and patients’ perspectives on psoriasis. <i>BMC Family Practice</i> , 2013, 14, 158.	2.9	55
301	Alemtuzumab and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013, 169, 184-186.	1.4	2
302	Dopamine is a novel, direct inducer of catagen in human scalp hair follicles <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2013, 168, 520-525.	1.4	19
303	Serum insulin-like growth factor 1 and facial ageing: high levels associate with reduced skin wrinkling in a cross-sectional study. <i>British Journal of Dermatology</i> , 2013, 168, 533-538.	1.4	23
304	Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche. <i>Journal of Pathology</i> , 2013, 231, 236-247.	2.1	201
305	Tumour Necrosis Factor Alpha, Interferon Gamma and Substance P Are Novel Modulators of Extrapituitary Prolactin Expression in Human Skin. <i>PLoS ONE</i> , 2013, 8, e60819.	1.1	25
306	A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 12-7.	0.4	9

#	ARTICLE	IF	CITATIONS
307	Utilizing the hair follicle to dissect the regulation and autocrine/paracrine activities of prolactin in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E1311-E1312.	1.8	12
308	Noninvasive Measurement of Skin Autofluorescence Is Increased in Patients with Systemic Sclerosis: An Indicator of Increased Advanced Glycation Endproducts?. <i>Journal of Rheumatology</i> , 2012, 39, 1654-1658.	1.0	17
309	Beyond skin: the need for a new approach to the management of psoriasis in primary care. <i>British Journal of General Practice</i> , 2012, 62, 568-569.	0.7	15
310	Investigational VEGF antagonists for psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 33-43.	1.9	32
311	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741.	0.6	101
312	Chemical consequences of cutaneous photoageing. <i>Chemistry Central Journal</i> , 2012, 6, 34.	2.6	23
313	Commentary: Biologics for psoriasis: steps to heaven 17. <i>British Journal of Dermatology</i> , 2012, 167, 715-716.	1.4	1
314	Biologics for psoriasis: current evidence and future use. <i>British Journal of Dermatology</i> , 2012, 167, 1-2.	1.4	4
315	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
316	So you want to be a clinical academic. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, C23-C25.	0.2	1
317	Differential expression of elastic fibre components in intrinsically aged skin. <i>Biogerontology</i> , 2012, 13, 37-48.	2.0	28
318	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012, 166, 189-195.	1.4	34
319	Lichen planopilaris following hair transplantation and face-lift surgery. <i>British Journal of Dermatology</i> , 2012, 166, 666-370.	1.4	64
320	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012, 166, 474-482.	1.4	59
321	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012, 166, 545-554.	1.4	108
322	No impairment of monocyteâ€ derived Langerhans cell phenotype or function in earlyâ€ onset psoriasis. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 40-47.	0.6	7
323	A temporal analysis of the central neural processing of itch. <i>British Journal of Dermatology</i> , 2012, 166, 994-1001.	1.4	27
324	Twenty top tips to triumph in dermatology. <i>British Journal of Dermatology</i> , 2012, 167, 445-446.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Primary cicatricial alopecias: a U.K. survey. <i>British Journal of Dermatology</i> , 2012, 167, 694-697.	1.4	24
326	Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. <i>British Journal of Dermatology</i> , 2012, 167, 563-569.	1.4	19
327	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 2-8.	1.3	8
328	In search of oral psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 1-5.	1.1	39
329	Exploring the role of prolactin in psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 115-118.	1.1	23
330	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 300-12.	0.4	54
331	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. <i>Journal of Dermatological Treatment</i> , 2011, 22, 187-193.	1.1	4
332	Evaluation of educational methods in dermatology and confidence levels: a national survey of UK medical students. <i>International Journal of Dermatology</i> , 2011, 50, 198-202.	0.5	28
333	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	28
334	The effect of ageing on phenotype and function of monocyte-derived Langerhans cells. <i>British Journal of Dermatology</i> , 2011, 165, 184-188.	1.4	20
335	What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 585-589.	0.6	10
336	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. <i>British Journal of Dermatology</i> , 2011, 164, 862-872.	1.4	121
337	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011, 12, 815-826.	0.6	69
338	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10.	1.1	690
339	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.5	68
340	In search of the source of hyperprolactinaemia in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 1060.	0.4	1
341	Does collapse of immune privilege in the hair-follicle bulge play a role in the pathogenesis of primary cicatricial alopecia?. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 637-644.	0.6	32
342	Evidence for the presence of bacteria in the blood of psoriasis patients. <i>Archives of Dermatological Research</i> , 2010, 302, 495-498.	1.1	50

#	ARTICLE	IF	CITATIONS
343	Low-dose ultraviolet radiation selectively degrades chromophore-rich extracellular matrix components. <i>Journal of Pathology</i> , 2010, 222, 32-40.	2.1	58
344	Review Article: A new wrinkle on old skin: the role of elastic fibres in skin ageing. <i>International Journal of Cosmetic Science</i> , 2010, 32, 330-339.	1.2	133
345	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 548-554.	1.3	135
346	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1371-1377.	1.3	39
347	Comparing biological therapies in psoriasis: implications for clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-14.	1.3	26
348	Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2010, 162, 1127-1131.	1.4	37
349	Management of psoriasis in pregnancy: time to deliver?. <i>British Journal of Dermatology</i> , 2010, 163, 235-235.	1.4	7
350	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2010, 163, 859-862.	1.4	23
351	What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 688-692.	0.6	6
352	Mind the (Gender) Gap: Does Prolactin Exert Gender and/or Site-Specific Effects on the Human Hair Follicle?. <i>Journal of Investigative Dermatology</i> , 2010, 130, 886-891.	0.3	40
353	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	9.4	918
354	Effects vs Improvement of Photoaged Skin—Reply. <i>Archives of Dermatology</i> , 2010, 146, .	1.7	0
355	A Tooth for an Eye: Cicatricial Pemphigoid and the Osteo-Odonto-Keratoprosthesis. <i>Archives of Dermatology</i> , 2010, 146, 1188-9.	1.7	4
356	Langerhans Cell Mobilization Distinguishes between Early-Onset and Late-Onset Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1940-1942.	0.3	22
357	Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. <i>Dermatology</i> , 2010, 221, 172-178.	0.9	55
358	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. <i>New England Journal of Medicine</i> , 2010, 362, 118-128.	13.9	773
359	Tissue section AFM: In situ ultrastructural imaging of native biomolecules. <i>Matrix Biology</i> , 2010, 29, 254-260.	1.5	98
360	The Future of Biological Therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 63-66.	1.6	18

#	ARTICLE	IF	CITATIONS
361	Why Some Women Look Young for Their Age. PLoS ONE, 2009, 4, e8021.	1.1	178
362	Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis and Rheumatism, 2009, 61, 1103-1111.	6.7	106
363	Liver X receptor β : maintenance of epidermal expression in intrinsic and extrinsic skin aging. Age, 2009, 31, 365-372.	3.0	2
364	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. British Journal of Dermatology, 2009, 160, 162-169.	1.4	48
365	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. British Journal of Dermatology, 2009, 160, 438-441.	1.4	64
366	Pilot study of dual-wavelength (532 and 633nm) laser Doppler imaging and infrared thermography of morphea. British Journal of Dermatology, 2009, 160, 864-867.	1.4	26
367	Care of patients with psoriasis: an audit of U.K. services in secondary care. British Journal of Dermatology, 2009, 160, 557-564.	1.4	27
368	How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. British Journal of Dermatology, 2009, 160, 482-501.	1.4	96
369	Alice, Eloj, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. British Journal of Dermatology, 2009, 161, 1-30.	1.4	6
370	A cosmetic "anti-ageing" product improves photoaged skin: a double-blind, randomized controlled trial. British Journal of Dermatology, 2009, 161, 419-426.	1.4	66
371	Evidence for an "anti-ageing" product may not be so clear as it appears: reply from authors. British Journal of Dermatology, 2009, 161, 1208-1209.	1.4	2
372	British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology, 2009, 161, 987-1019.	1.4	412
373	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clinical and Experimental Dermatology, 2009, 34, 415-416.	0.6	19
374	An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging. Clinical and Experimental Dermatology, 2009, 34, 618-620.	0.6	2
375	Defining cancer risk in dermatomyositis. Part I. Clinical and Experimental Dermatology, 2009, 34, 451-455.	0.6	54
376	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clinical and Experimental Dermatology, 2009, 34, 561-565.	0.6	38
377	What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. Clinical and Experimental Dermatology, 2009, 34, 664-667.	0.6	7
378	Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes and Immunity, 2009, 10, 654-658.	2.2	53

#	ARTICLE	IF	CITATIONS
379	Severely Photosensitive Psoriasis: A Phenotypically Defined Patient Subset. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2861-2867.	0.3	25
380	Efficacy of anti-aging products for periorbital wrinkles as measured by 3D imaging. <i>Journal of Cosmetic Dermatology</i> , 2009, 8, 228-233.	0.8	30
381	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1374-1382.	1.3	88
382	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
383	Future Therapeutic Directions for the Treatment of Psoriasis. <i>Actas Dermo-sifilograficas</i> , 2009, 100, 28-31.	0.2	1
384	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009, 1, 72.	3.6	14
385	Diminished Neural and Cognitive Responses to Facial Expressions of Disgust in Patients with Psoriasis: A Functional Magnetic Resonance Imaging Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2613-2619.	0.3	49
386	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 15-21.	0.3	1
387	Repair of photoaged dermal matrix by topical application of a cosmetic anti-aging product. <i>British Journal of Dermatology</i> , 2008, 158, 472-477.	1.4	66
388	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. <i>Archives of Dermatological Research</i> , 2008, 300, 537-544.	1.1	45
389	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3705-3709.	6.7	122
390	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. <i>Experimental Dermatology</i> , 2008, 17, 228-229.	1.4	29
391	Viewpoint 2. <i>Experimental Dermatology</i> , 2008, 17, 230-231.	1.4	0
392	No Association between Polymorphisms in the Interleukin-15 Gene and Early-Onset Psoriasis in a UK Cohort Suggests Heterogeneity for this Susceptibility Locus Identified in Chinese Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2904-2905.	0.3	6
393	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1925-1929.	0.3	109
394	Humoral Autoimmune Responses to the Squamous Cell Carcinoma Antigen Protein Family in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2219-2224.	0.3	35
395	Polymorphisms in the IL-12 β and IL-23R Genes Are Associated with Psoriasis of Early Onset in a UK Cohort. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1325-1327.	0.3	74
396	The Effects of Acute Social Stress on Epidermal Langerhans' Cell Frequency and Expression of Cutaneous Neuropeptides. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1273-1279.	0.3	48

#	ARTICLE	IF	CITATIONS
397	Psoriasis: consensus on topical therapies. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 859-870.	1.3	29
398	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. British Journal of Dermatology, 2008, 158, 962-968.	1.4	41
399	Management of primary cicatricial alopecias: options for treatment. British Journal of Dermatology, 2008, 159, 1-22.	1.4	104
400	Making a point about the safe disposal of sharps in patients on biological therapies. British Journal of Dermatology, 2008, 159, 491-492.	1.4	4
401	A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology, 2008, 159, 942-951.	1.4	71
402	Methotrexate for psoriasis in the era of biological therapy. Clinical and Experimental Dermatology, 2008, 33, 551-554.	0.6	61
403	Topical Treatments for Scalp Psoriasis. Drugs, 2008, 68, 2293-2302.	4.9	12
404	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology, 2008, 58, 224-231.	0.6	157
405	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clinics in Dermatology, 2008, 26, 438-447.	0.8	67
406	Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Current Medical Research and Opinion, 2008, 24, 1237-1254.	0.9	46
407	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. Human Molecular Genetics, 2008, 17, 1938-1945.	1.4	176
408	Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Review of Dermatology, 2008, 3, 657-665.	0.3	44
409	Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus. Dermatology, 2008, 217, 268-275.	0.9	33
410	A review of tazarotene in the treatment of photodamaged skin. Clinical Interventions in Aging, 2008, Volume 3, 71-76.	1.3	16
411	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. Experimental Dermatology, 2008, 17, 228-240.	1.4	9
412	The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. Journal of Clinical Investigation, 2008, 118, 3151-3159.	3.9	145
413	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Annals of the Rheumatic Diseases, 2007, 67, 672-676.	0.5	149
414	Nuclear Hormone Receptors in Human Skin. Hormone and Metabolic Research, 2007, 39, 96-105.	0.7	57

#	ARTICLE	IF	CITATIONS
415	Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. <i>Journal of Medical Genetics</i> , 2007, 45, 114-116.	1.5	139
416	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 677-682.	0.5	92
417	Balancing the Benefits and Risks of Drug Treatment. <i>Archives of Dermatology</i> , 2007, 143, 1175-9.	1.7	58
418	Pathogenesis and clinical features of psoriasis. <i>Lancet, The</i> , 2007, 370, 263-271.	6.3	1,617
419	Current and future management of psoriasis. <i>Lancet, The</i> , 2007, 370, 272-284.	6.3	268
420	Illness perception in individuals with atopic dermatitis. <i>Psychology, Health and Medicine</i> , 2007, 12, 433-444.	1.3	56
421	Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg. <i>Trials</i> , 2007, 8, 3.	0.7	8
422	Altered claudin expression is a feature of chronic plaque psoriasis. <i>Journal of Pathology</i> , 2007, 212, 450-458.	2.1	70
423	Increased Blood Levels of IgG Reactive with Secreted <i>Streptococcus pyogenes</i> Proteins in Chronic Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1337-1342.	0.3	34
424	Filaggrin Null Alleles Are Not Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1878-1882.	0.3	41
425	Salicyloyl-phytosphingosine: a novel agent for the repair of photoaged skin. <i>International Journal of Cosmetic Science</i> , 2007, 29, 319-329.	1.2	27
426	A classification of psoriasis vulgaris according to phenotype. <i>British Journal of Dermatology</i> , 2007, 156, 258-262.	1.4	257
427	The Greater Patient concept. <i>British Journal of Dermatology</i> , 2007, 158, 071027220355005-???	1.4	11
428	Alcohol consumption and psychological distress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 158, 071115063928007-???	1.4	108
429	Inpatient management of psoriasis: a multicentre service review to establish national admission standards. <i>British Journal of Dermatology</i> , 2007, 158, 266-272.	1.4	15
430	Systemic ciclosporin and tacrolimus in dermatology. <i>Dermatologic Therapy</i> , 2007, 20, 239-250.	0.8	72
431	Guidelines for Logbook for registration of training activities in dermatology and venereology: report from the Board of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 850-851.	1.3	0
432	An Examination of the Psychometric Properties and Factor Structure of the Feelings of Stigmatization Questionnaire. <i>Journal of Clinical Psychology in Medical Settings</i> , 2007, 14, 248-257.	0.8	5

#	ARTICLE	IF	CITATIONS
433	Anti-aging Effects of Retinoids and Mechanisms of Action. Basic and Clinical Dermatology, 2007, , 77-102.	0.1	0
434	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. European Journal of Dermatology, 2007, 17, 381-6.	0.3	28
435	Photoageing: the darker side of the sun. Photochemical and Photobiological Sciences, 2006, 5, 160-164.	1.6	39
436	A European perspective on the challenges of managing psoriasis. Journal of the American Academy of Dermatology, 2006, 54, S81-S84.	0.6	22
437	Interventions for chronic palmoplantar pustulosis. The Cochrane Library, 2006, , CD001433.	1.5	46
438	Adherence to treatment in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 370-379.	1.3	128
439	The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 060628090810004-???.	1.3	29
440	The use of retinoids in the treatment of photoaging. Dermatologic Therapy, 2006, 19, 297-305.	0.8	50
441	The CX3CL1-CX3CR1 system and psoriasis. Experimental Dermatology, 2006, 15, 900-903.	1.4	21
442	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. British Journal of Dermatology, 2006, 154, 345-352.	1.4	74
443	Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. British Journal of Dermatology, 2006, 154, 977-978.	1.4	185
444	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. British Journal of Dermatology, 2006, 154, 1161-1168.	1.4	116
445	Update on the use of ciclosporin in immune-mediated dermatoses. British Journal of Dermatology, 2006, 155, 1-16.	1.4	78
446	The impact of psoriasis guidelines on appropriateness of referral from primary to secondary care: a randomized controlled trial. British Journal of Dermatology, 2006, 155, 393-400.	1.4	28
447	Striae gravidarum in primiparae. British Journal of Dermatology, 2006, 155, 965-969.	1.4	116
448	The role of neuropeptides in psoriasis. British Journal of Dermatology, 2006, 155, 876-882.	1.4	122
449	Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. British Journal of Dermatology, 2006, 155, 1236-1241.	1.4	33
450	Proteomic analysis of suction blister fluid isolated from human skin. Clinical and Experimental Dermatology, 2006, 31, 445-448.	0.6	28

#	ARTICLE	IF	CITATIONS
451	Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 453-459.	0.3	105
452	Anti-TNF drugs in psoriasis and IBD - Where are we going?. <i>Future Prescriber</i> , 2006, 7, 14-20.	0.1	0
453	Biological therapy for psoriasis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006, 67, 184-187.	0.2	2
454	Infliximab for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 797-805.	1.4	37
455	A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 90-95.	1.1	50
456	Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. <i>Gut</i> , 2006, 55, 505-509.	6.1	524
457	Pyoderma Gangrenosum Masquerading as Dermatitis Artefacta. <i>Archives of Dermatology</i> , 2006, 142, 1508.	1.7	13
458	Impaired Langerhans cell migration in psoriasis. <i>Journal of Experimental Medicine</i> , 2006, 203, 953-960.	4.2	109
459	Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S72-8.	0.4	28
460	Modern management of psoriasis. <i>Clinical Medicine</i> , 2005, 5, 564-568.	0.8	2
461	Pathogenic aspects of cutaneous photoaging. <i>Journal of Cosmetic Dermatology</i> , 2005, 4, 230-236.	0.8	37
462	Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. <i>British Journal of Dermatology</i> , 2005, 152, 489-504.	1.4	35
463	Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. <i>British Journal of Dermatology</i> , 2005, 152, 1182-1186.	1.4	18
464	Ciclosporin in psoriasis consensus statement. <i>British Journal of Dermatology</i> , 2005, 152, 811-811.	1.4	0
465	Ciclosporin in psoriasis consensus statement: reply from authors. <i>British Journal of Dermatology</i> , 2005, 152, 811-811.	1.4	1
466	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>British Journal of Dermatology</i> , 2005, 152, 597-615.	1.4	165
467	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005, 152, 1219-1227.	1.4	53
468	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , 2005, 152, 1304-1312.	1.4	666

#	ARTICLE	IF	CITATIONS
469	Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. <i>British Journal of Dermatology</i> , 2005, 153, 549-551.	1.4	52
470	Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 1114-1120.	1.4	105
471	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 869-873.	1.4	27
472	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005, 153, 486-497.	1.4	245
473	Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. <i>British Journal of Dermatology</i> , 2005, 153, 1192-1199.	1.4	125
474	The Major Psoriasis Susceptibility Locus PSORS1 Is not a Risk Factor for Late-Onset Psoriasis. <i>Journal of Investigative Dermatology</i> , 2005, 124, 103-106.	0.3	85
475	Controversies in Experimental Dermatology. Viewpoint 5. <i>Experimental Dermatology</i> , 2005, 14, 398-399.	1.4	0
476	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005, 52, 1694-1699.	6.7	266
477	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
478	Worry and Pathological Worry in Patients with Psoriasis: Cross Sectional and Longitudinal Analyses of the Penn State Worry Questionnaire (PSWQ) in Four Samples of Patients. <i>Journal of Clinical Psychology in Medical Settings</i> , 2005, 12, 143-152.	0.8	9
479	Guideline for anti-TNF- α therapy in psoriatic arthritis. <i>Rheumatology</i> , 2005, 44, 390-397.	0.9	125
480	Treatment of photoaged skin with a cream containing 0.05% isotretinoin and sunscreens. <i>Journal of Dermatological Treatment</i> , 2005, 16, 79-86.	1.1	19
481	Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate. <i>Dermatology</i> , 2005, 211, 256-263.	0.9	18
482	Interventions for photodamaged skin. , 2005, , CD001782.		40
483	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet</i> , The, 2005, 366, 1367-1374.	6.3	975
484	Psychologic Factors in Psoriasis: Consequences, Mechanisms, and Interventions. <i>Dermatologic Clinics</i> , 2005, 23, 681-694.	1.0	212
485	Efalizumab. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 119-120.	3.3	1
486	Optimal Management of Severe Plaque Form of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 283-294.	3.3	18

#	ARTICLE	IF	CITATIONS
487	Adversarial growth in patients undergoing treatment for psoriasis: A prospective study of the ability of patients to construe benefits from negative events. <i>Psychology, Health and Medicine</i> , 2005, 10, 44-56.	1.3	26
488	Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 468-473.	0.6	73
489	Alexithymia in patients with psoriasis. <i>Journal of Psychosomatic Research</i> , 2005, 58, 89-96.	1.2	73
490	Cytokines and Langerhans cell mobilisation in mouse and man. <i>Cytokine</i> , 2005, 32, 67-70.	1.4	104
491	Psoriasis: epidemiology, clinical features, and quality of life. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii18-ii23.	0.5	605
492	T-Cell-Targeted Biologicals for Psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 157-161.	3.1	8
493	Glucocorticoid Sensitivity Is Determined by a Specific Glucocorticoid Receptor Haplotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 892-897.	1.8	163
494	Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin. <i>British Journal of Dermatology</i> , 2004, 150, 1217-1218.	1.4	26
495	Streptococcal infection may make psoriasis worse but do antibiotics help?. <i>British Journal of Dermatology</i> , 2004, 151, 244-245.	1.4	3
496	CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. <i>British Journal of Dermatology</i> , 2004, 151, 675-678.	1.4	22
497	Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. <i>British Journal of Dermatology</i> , 2004, 151, 1227-1233.	1.4	116
498	Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. <i>British Journal of Dermatology</i> , 2004, 151, 1219-1226.	1.4	68
499	Competency assessment of dermatology trainees in the UK. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 571-575.	0.6	9
500	Ciclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , 2004, 150, 11-23.	1.4	132
501	Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation. <i>Experimental Dermatology</i> , 2004, 13, 452-460.	1.4	25
502	Divergent Beliefs About Psoriasis Are Associated with Increased Psychological Distress. <i>Journal of Investigative Dermatology</i> , 2004, 123, 49-56.	0.3	50
503	Macrophage Migration Inhibitory Factor Gene Polymorphism is Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2004, 123, 484-487.	0.3	74
504	Retinoic acid receptor ? expression and cutaneous ageing. <i>Mechanisms of Ageing and Development</i> , 2004, 125, 465-473.	2.2	19

#	ARTICLE	IF	CITATIONS
505	Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: Results from a patient preference controlled trial. <i>British Journal of Clinical Psychology</i> , 2004, 43, 65-82.	1.7	97
506	Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset. <i>Journal of Investigative Dermatology</i> , 2004, 122, 209-215.	0.3	138
507	Therapeutic potential of macrolide immunosuppressants in dermatology. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 125-137.	1.9	4
508	Psoriasis: future research needs and goals for the twenty-first century. <i>Dermatologic Clinics</i> , 2004, 22, 493-499.	1.0	11
509	Associations between UVR exposure and basal cell carcinoma site and histology. <i>Cancer Letters</i> , 2004, 216, 191-197.	3.2	19
510	The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. <i>Journal of Psychosomatic Research</i> , 2004, 57, 195-200.	1.2	127
511	Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. <i>Journal of Behavioral Medicine</i> , 2003, 26, 211-224.	1.1	46
512	Epidermal Langerhans cell migration and sensitisation to chemical allergens. <i>Apms</i> , 2003, 111, 797-804.	0.9	70
513	A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. <i>Experimental Dermatology</i> , 2003, 12, 506-509.	1.4	26
514	Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis. <i>Journal of Investigative Dermatology</i> , 2003, 120, 627-632.	0.3	190
515	Resetting the Research Agenda for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2003, 120, ix-x.	0.3	10
516	The immunological basis of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 1-5.	1.3	52
517	Circulating natural killer cells in psoriasis. <i>British Journal of Dermatology</i> , 2003, 149, 160-164.	1.4	85
518	Stigmatization and psoriasis. <i>British Journal of Dermatology</i> , 2003, 149, 209-211.	1.4	41
519	Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. <i>British Journal of Dermatology</i> , 2003, 149, 323-331.	1.4	127
520	Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 64-69.	0.6	38
521	Keloidal scleroderma. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 171-173.	0.6	12
522	Papuloerythroderma of Ofuji associated with acute myeloid leukaemia. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 277-279.	0.6	11

#	ARTICLE	IF	CITATIONS
523	IL-1 β -induced Langerhans cell migration and TNF- α production in human skin: regulation by lactoferrin. <i>Clinical and Experimental Immunology</i> , 2003, 132, 352-359.	1.1	97
524	Assessment of adapalene gel for the treatment of actinic keratoses and lentiginos: A randomized trial. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 83-90.	0.6	105
525	Psychological Distress Impairs Clearance of Psoriasis in Patients Treated With Photochemotherapy. <i>Archives of Dermatology</i> , 2003, 139, 752-6.	1.7	199
526	An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis. <i>Archives of Dermatology</i> , 2003, 139, 719-27.	1.7	338
527	Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 μ g/g ointment; no correlation with extent of psoriasis. <i>Journal of Dermatological Treatment</i> , 2003, 14, 14-21.	1.1	19
528	Photoageing. , 2003, , 399-401.		0
529	Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. <i>Biochemistry and Cell Biology</i> , 2002, 80, 103-107.	0.9	54
530	Immunotherapy for psoriasis: from serendipity to selectivity. <i>Lancet, The</i> , 2002, 359, 279-280.	6.3	23
531	An investigation of the effect of prolonged glove wearing on the hand skin health of dental healthcare workers. <i>Journal of Dentistry</i> , 2002, 30, 233-241.	1.7	9
532	Natural killer and natural killer-T cells in psoriasis. <i>Archives of Dermatological Research</i> , 2002, 294, 363-369.	1.1	107
533	Tumour necrosis factor- α -induced migration of human Langerhans cells: the influence of ageing. <i>British Journal of Dermatology</i> , 2002, 146, 32-40.	1.4	114
534	Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2002, 146, 414-422.	1.4	66
535	A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. <i>British Journal of Dermatology</i> , 2002, 146, 458-465.	1.4	218
536	Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. <i>British Journal of Dermatology</i> , 2002, 146, 824-831.	1.4	135
537	Novel immune-based therapies for psoriasis. <i>British Journal of Dermatology</i> , 2002, 146, 546-551.	1.4	49
538	Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , 2002, 147, 299-307.	1.4	47
539	Enumeration of the frequency of Langerhans cells in epidermis. <i>British Journal of Dermatology</i> , 2002, 147, 1277-1278.	1.4	0
540	Enumeration of the frequency of Langerhans cells in epidermis: reply from authors. <i>British Journal of Dermatology</i> , 2002, 147, 1278-1278.	1.4	0

#	ARTICLE	IF	CITATIONS
541	Recent advances in cutaneous angiogenesis. <i>British Journal of Dermatology</i> , 2002, 147, 418-425.	1.4	53
542	Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2002, 147, 701-709.	1.4	20
543	Fibulin-2 and its association with fibrillin-rich microfibrils in the papillary dermis of photoaged skin. <i>British Journal of Dermatology</i> , 2002, 146, 712-712.	1.4	1
544	Danger signals and skin sensitization. <i>British Journal of Dermatology</i> , 2002, 147, 613-613.	1.4	25
545	Patients' strategies for coping with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 177-184.	0.6	59
546	Cytokine blocking agents in dermatology. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 585-590.	0.6	46
547	Wirksamkeit und Sicherheit von Tacalcitol-Salbe in der Langzeitanwendung bei chronischer Plaque Psoriasis. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. <i>Zeitschrift F�r Hautkrankheiten</i> , 2002, 77, 424-432.	0.0	4
548	Die Zytokin-Blocker in der Dermatologie. Cytokine blocking agents in dermatology. <i>Zeitschrift F�r Hautkrankheiten</i> , 2002, 77, 663-668.	0.0	0
549	Psychological stress, distress and disability in patients with psoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia. <i>British Journal of Clinical Psychology</i> , 2002, 41, 157-174.	1.7	179
550	Topical retinoids for the ageing face. , 2002, , 13-23.		0
551	The macrolide immunosuppressants in dermatology: mechanisms of action. <i>European Journal of Dermatology</i> , 2002, 12, 618-22.	0.3	68
552	Epidermal and dermal abnormalities. <i>European Journal of Dermatology</i> , 2002, 12, XIX-XX.	0.3	1
553	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 643-651.	0.6	142
554	Physical and psychologic measures are necessary to assess overall psoriasis severity. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 72-76.	0.6	153
555	The contribution of perceptions of stigmatisation to disability in patients with psoriasis. <i>Journal of Psychosomatic Research</i> , 2001, 50, 11-15.	1.2	250
556	Distribution and expression of type VI collagen in photoaged skin. <i>British Journal of Dermatology</i> , 2001, 144, 751-759.	1.4	39
557	Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. <i>British Journal of Dermatology</i> , 2001, 144, 715-725.	1.4	82
558	Cytokine gene polymorphisms in psoriasis. <i>British Journal of Dermatology</i> , 2001, 144, 849-853.	1.4	77

#	ARTICLE	IF	CITATIONS
559	Activation of oral keratinocytes by mercuric chloride: relevance to dental amalgam-induced oral lichenoid reactions. <i>British Journal of Dermatology</i> , 2001, 144, 1024-1032.	1.4	16
560	Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2001, 145, 546-553.	1.4	107
561	Patient satisfaction with teledermatology is related to perceived quality of life. <i>British Journal of Dermatology</i> , 2001, 145, 911-917.	1.4	95
562	The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis.. <i>British Journal of Dermatology</i> , 2001, 145, 1027-1028.	1.4	7
563	A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2001, 145, 886-890.	1.4	83
564	A systematic review of treatments for guttate psoriasis. <i>British Journal of Dermatology</i> , 2001, 145, 891-894.	1.4	32
565	Ascomycin: an advance in the management of atopic dermatitis. <i>British Journal of Dermatology</i> , 2001, 144, 679-681.	1.4	23
566	Psoriasis 2000: the state-of-the-art today ... and tomorrow. <i>British Journal of Dermatology</i> , 2001, 144, 1-1.	1.4	0
567	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001, 144, 37-43.	1.4	41
568	A 62-year-old man presenting with widespread nodulo-ulcerative cutaneous lesions. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 115-119.	0.6	1
569	Folliculitis decalvans. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 120-122.	0.6	58
570	Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 27-29.	0.6	67
571	Psychological influences in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 338-342.	0.6	106
572	The role of retinoids in the prevention and repair of aged and photoaged skin. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 613-618.	0.6	51
573	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 648-653.	0.6	122
574	A Short-Term Screening Protocol, Using Fibrillin-1 as a Reporter Molecule, for Photoaging Repair Agents. <i>Journal of Investigative Dermatology</i> , 2001, 116, 672-678.	0.3	70
575	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001, 144, 37-43.	1.4	32
576	Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2001, 145, 438-445.	1.4	133

#	ARTICLE	IF	CITATIONS
577	Topical tacrolimus in the management of peristomal pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2001, 12, 13-17.	1.1	98
578	Patient satisfaction with store-and-forward teledermatology. <i>Journal of Telemedicine and Telecare</i> , 2001, 7, 45-46.	1.4	24
579	Life threatening complications of dermatological therapy. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 217-218.	0.6	0
580	Interventions for guttate psoriasis. <i>The Cochrane Library</i> , 2000, , CD001213.	1.5	15
581	Basal cell carcinoma. <i>Cancer</i> , 2000, 89, 1012-1018.	2.0	40
582	REVIEW Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. <i>British Journal of Dermatology</i> , 2000, 142, 401-412.	1.4	211
583	The Salford Psoriasis Index: an holistic measure of psoriasis severity. <i>British Journal of Dermatology</i> , 2000, 142, 728-732.	1.4	130
584	Nailfold video capillaroscopy in psoriasis. <i>British Journal of Dermatology</i> , 2000, 142, 1171-1176.	1.4	72
585	â€Brooke of Manchesterâ€™. <i>British Journal of Dermatology</i> , 2000, 143, 26-29.	1.4	0
586	The spectrum of skin disorders in abdominal stoma patients. <i>British Journal of Dermatology</i> , 2000, 143, 1248-1260.	1.4	168
587	The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 265-268.	0.6	19
588	Langerhans cell migration. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 413-418.	0.6	130
589	Topical sucralfate in the management of peristomal skin disease: an open study. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 584-588.	0.6	36
590	Therapeutic strategies for psoriasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 1-10.	0.7	94
591	Mobilization of epidermal Langerhans cells - reply from the authors. <i>British Journal of Dermatology</i> , 2000, 143, 894-894.	1.4	3
592	Pathological worrying, illness perceptions and disease severity in patients with psoriasis. <i>British Journal of Health Psychology</i> , 2000, 5, 71-82.	1.9	94
593	Investigation of Cytomegalovirus and Human Herpes Viruses 6 and 7 as Possible Causative Antigens in Psoriasis. <i>Acta Dermato-Venereologica</i> , 2000, 80, 404-406.	0.6	14
594	Combination Regimens of Topical Calcipotriene in Chronic Plaque Psoriasis. <i>Archives of Dermatology</i> , 2000, 136, 1536-43.	1.7	27

#	ARTICLE	IF	CITATIONS
595	Parastomal pyoderma gangrenosum: Clinical features and management. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 992-1002.	0.6	126
596	Peristomal dermatoses: A novel indication for topical steroid lotions. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 679-682.	0.6	57
597	Cost-Effectiveness Analysis of Topical Calcipotriol versus Short- Contact Dithranol. <i>Pharmacoeconomics</i> , 2000, 18, 469-476.	1.7	16
598	Antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>The Cochrane Library</i> , 2000, , CD001976.	1.5	54
599	Photoageing. , 2000, , 437-440.		0
600	Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. <i>British Journal of Dermatology</i> , 1999, 140, 562-564.	1.4	37
601	Digital teledermatology for skin tumours: A preliminary assessment using a receiver operating characteristics (ROC) analysis. <i>Journal of Telemedicine and Telecare</i> , 1999, 5, 57-58.	1.4	34
602	Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. <i>British Journal of Dermatology</i> , 1999, 141, 185-191.	1.4	237
603	Tumour necrosis factor- α induces Langerhans cell migration in humans. <i>British Journal of Dermatology</i> , 1999, 141, 192-200.	1.4	89
604	Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. <i>British Journal of Dermatology</i> , 1999, 141, 279-282.	1.4	79
605	Intermittent short courses of cyclosporin (Neoral [®]) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. <i>British Journal of Dermatology</i> , 1999, 141, 283-291.	1.4	124
606	Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. <i>British Journal of Dermatology</i> , 1999, 141, 1054-1060.	1.4	170
607	The British Association of Dermatologists guidelines for the management of skin disease. <i>British Journal of Dermatology</i> , 1999, 141, 396-397.	1.4	29
608	Dowling Oration delivered at the Royal College of Physicians, London, Friday 5 June 1998. Retinoids: renaissance and reformation. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 329-335.	0.6	6
609	Chronic granulomatous disease and acute neutrophilic dermatosis. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 368-371.	0.6	12
610	Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon?. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 446-448.	0.6	21
611	Fibrillin-Rich Microfibrils are Reduced in Photoaged Skin. Distribution at the Dermal-€"Epidermal Junction. <i>Journal of Investigative Dermatology</i> , 1999, 112, 782-787.	0.3	156
612	Drug Treatment of Photoaged Skin. <i>Drugs and Aging</i> , 1999, 14, 289-301.	1.3	26

#	ARTICLE	IF	CITATIONS
613	Patients with psoriasis and their compliance with medication. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 581-583.	0.6	105
614	Differential Expression of Peroxisome Proliferator-Activated Receptor Subtypes During the Differentiation of Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1116-1121.	0.3	141
615	Quality of life measures in psoriasis: a critical appraisal of their quality. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 391-398.	0.7	57
616	Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. <i>British Journal of Dermatology</i> , 1998, 138, 77-83.	1.4	85
617	Fibrillin microfibrils are reduced in skin exhibiting striae distensae. <i>British Journal of Dermatology</i> , 1998, 138, 931-937.	1.4	153
618	Comparison of teleconsultations and face-to-face consultations: preliminary results of a United Kingdom multicentre teledermatology study. <i>British Journal of Dermatology</i> , 1998, 139, 81-87.	1.4	163
619	All-trans retinoic acid compromises desmosome expression in human epidermis. <i>British Journal of Dermatology</i> , 1998, 139, 577-584.	1.4	26
620	What patients with psoriasis believe about their condition. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 196-201.	0.6	152
621	Assessment of topical retinoids for the treatment of Far-East Asian skin. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, S104-S107.	0.6	6
622	GMDP and psoriasis. <i>Lancet</i> , The, 1998, 352, 1857.	6.3	1
623	A painful spot on the nose. <i>Lancet</i> , The, 1998, 351, 566.	6.3	1
624	Immunotherapy of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 1, 175-184.	0.6	2
625	Assessing illness-related stress in psoriasis: The psychometric properties of the Psoriasis Life Stress Inventory. <i>Journal of Psychosomatic Research</i> , 1997, 42, 467-475.	1.2	103
626	Treatment Options for Photodamaged Skin. <i>Skin Pharmacology and Physiology</i> , 1997, 10, 1-11.	1.1	1
627	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997, 137, 344-350.	1.4	38
628	Multiple glomus tumours, Coats' disease and basic fibroblast growth factor. <i>British Journal of Dermatology</i> , 1997, 137, 454-456.	1.4	9
629	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997, 137, 755-760.	1.4	126
630	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997, 137, 755-760.	1.4	145

#	ARTICLE	IF	CITATIONS
631	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997, 137, 344-350.	1.4	51
632	A comparison of wire brush and diamond fraisesuperficial dermabrasion for photoaged skin. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 235-243.	0.6	40
633	Topical retinoic acid for photoaged skin: Therapeutic effects and mechanisms. <i>Journal of Dermatological Treatment</i> , 1996, 7, S23-S27.	1.1	2
634	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996, 134, 431-436.	1.4	2
635	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996, 135, 60-64.	1.4	25
636	Topical retinoids and cutaneous biology. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 1-10.	0.6	24
637	Psoriasis, T Cells and Autoimmunity. <i>Journal of the Royal Society of Medicine</i> , 1996, 89, 315-319.	1.1	58
638	Topical tretinoin (retinoic acid) improves early stretch marks. <i>Archives of Dermatology</i> , 1996, 132, 519-526.	1.7	77
639	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996, 135, 60-64.	1.4	27
640	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996, 134, 431-436.	1.4	9
641	Down-regulation of Langerhans cell protein kinase C- β isoenzyme expression in inflammatory and hyperplastic dermatoses. <i>British Journal of Dermatology</i> , 1995, 133, 157-167.	1.4	29
642	The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. <i>British Journal of Dermatology</i> , 1995, 133, 823-829.	1.4	31
643	Application of Retinol to Human Skin In Vivo Induces Epidermal Hyperplasia and Cellular Retinoid Binding Proteins Characteristic of Retinoic Acid but Without Measurable Retinoic Acid Levels or Irritation. <i>Journal of Investigative Dermatology</i> , 1995, 105, 549-556.	0.3	277
644	Immunopathogenesis and Immunotherapy of Psoriasis. <i>Dermatologic Clinics</i> , 1995, 13, 739-749.	1.0	31
645	Two Concentrations of Topical Tretinoin (Retinoic Acid) Cause Similar Improvement of Photoaging but Different Degrees of Irritation. <i>Archives of Dermatology</i> , 1995, 131, 1037.	1.7	100
646	Retinoic acid antagonizes basal as well as coal tar and glucocorticoid-induced cytochrome P4501A1 expression in human skin. <i>Carcinogenesis</i> , 1995, 16, 519-524.	1.3	19
647	Reduced Type I and Type III Procollagens in Photodamaged Adult Human Skin. <i>Journal of Investigative Dermatology</i> , 1995, 105, 285-290.	0.3	340
648	Prolonged occlusion in the treatment of psoriasis: A clinical and immunohistologic study. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 618-622.	0.6	40

#	ARTICLE	IF	CITATIONS
649	Topical auranofin ointment for the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 517-519.	0.6	12
650	A clinical and histologic mycosis fungoides simulans occurring as a T-cell infiltrate coexisting with B-cell leukemia cutis. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 341-345.	0.6	22
651	Contact dermatitis from topical auranofin. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 813-814.	0.6	13
652	Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. <i>Archives of Dermatology</i> , 1995, 131, 1037-1044.	1.7	84
653	Efficacy of topical cyclosporin a in the treatment of alopecia areata. <i>Journal of Dermatological Treatment</i> , 1994, 5, 77-79.	1.1	3
654	Cutaneous Leukocyte Trafficking and Psoriasis. <i>Archives of Dermatology</i> , 1994, 130, 494.	1.7	23
655	Human in vivo pharmacology of topical retinoids. <i>Archives of Dermatological Research</i> , 1994, 287, 53-60.	1.1	24
656	Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: A vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 76-84.	0.6	95
657	Cutaneous leukocyte trafficking and psoriasis. <i>Archives of Dermatology</i> , 1994, 130, 494-499.	1.7	23
658	Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. <i>Archives of Dermatology</i> , 1994, 130, 727-733.	1.7	227
659	Clinical improvement following dermabrasion of photoaged skin correlates with synthesis of collagen I. <i>Archives of Dermatology</i> , 1994, 130, 1136-1142.	1.7	54
660	Comparison of CD271 (Adapalene) and All-Trans Retinoic Acid in Human Skin: Dissociation of Epidermal Effects and CRABP-II mRNA Expression. <i>Journal of Investigative Dermatology</i> , 1993, 101, 325-328.	0.3	43
661	Differential Expression of Protein Kinase C Isoenzymes in Normal and Psoriatic Adult Human Skin: Reduced Expression of Protein Kinase C- β II in Psoriasis. <i>Journal of Investigative Dermatology</i> , 1993, 101, 553-559.	0.3	81
662	Stimulus-Selective Induction of CRABP-II mRNA: A Marker for Retinoic Acid Action in Human Skin. <i>Journal of Investigative Dermatology</i> , 1993, 100, 356-359.	0.3	70
663	Differential Regulation of Tyrosinase Activity in Skin of White and Black Individuals In Vivo by Topical Retinoic Acid. <i>Journal of Investigative Dermatology</i> , 1993, 100, 800-805.	0.3	37
664	An in vivo experimental model for effects of topical retinoic acid in human skin. <i>British Journal of Dermatology</i> , 1993, 129, 389-394.	1.4	78
665	Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. <i>British Journal of Dermatology</i> , 1993, 129, 415-421.	1.4	225
666	Inflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosis. <i>British Journal of Dermatology</i> , 1993, 129, 324-326.	1.4	29

#	ARTICLE	IF	CITATIONS
667	CD1 gene expression in human skin. <i>Journal of Dermatological Science</i> , 1993, 6, 206-213.	1.0	20
668	Effect of Tretinoin on Collagen Formation in Photodamaged Skin. <i>New England Journal of Medicine</i> , 1993, 329, 2038-2039.	13.9	0
669	Restoration of Collagen Formation in Photodamaged Human Skin by Tretinoin (Retinoic Acid). <i>New England Journal of Medicine</i> , 1993, 329, 530-535.	13.9	464
670	Topical Tretinoin (Retinoic Acid) Therapy for Hyperpigmented Lesions Caused by Inflammation of the Skin in Black Patients. <i>New England Journal of Medicine</i> , 1993, 328, 1438-1443.	13.9	192
671	Tretinoin for Hyperpigmentation in Black Patients. <i>New England Journal of Medicine</i> , 1993, 329, 1503-1503.	13.9	6
672	Topical Retinoic Acid for Photoaging: Clinical Response and Underlying Mechanisms. <i>Skin Pharmacology and Physiology</i> , 1993, 6, 70-77.	1.1	32
673	Curly Lusterless Hair: Anatomic Surface Changes on Transplanted Hair Shafts. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1993, 19, 1129-1130.	0.8	5
674	Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. <i>Archives of Dermatology</i> , 1993, 129, 866-869.	1.7	76
675	Topical Tretinoin (Retinoic Acid) Treatment for Liver Spots Associated with Photodamage. <i>New England Journal of Medicine</i> , 1992, 326, 368-374.	13.9	168
676	A Photonumeric Scale for the Assessment of Cutaneous Photodamage. <i>Archives of Dermatology</i> , 1992, 128, 347.	1.7	185
677	A Photonumeric Scale for the Assessment of Cutaneous Photodamage-Reply. <i>Archives of Dermatology</i> , 1992, 128, 1407.	1.7	0
678	Psoriasis. I. Pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 98-101.	0.6	7
679	Failure of reticular erythematous mucinosis to respond to cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 825-828.	0.6	40
680	Immunological mechanisms involved in psoriasis. <i>Seminars in Immunopathology</i> , 1992, 13, 441-54.	4.0	27
681	Differential Modulation of Transforming Growth Factor- β 1 Expression and Mucin Deposition by Retinoic Acid and Sodium Lauryl Sulfate in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 98, 102-108.	0.3	52
682	Acute or Chronic Topical Retinoic Acid Treatment of Human Skin In Vivo Alters the Expression of Epidermal Transglutaminase, Loricrin, Involucrin, Filaggrin, and Keratins 6 and 13 but not Keratins 1, 10, and 14. <i>Journal of Investigative Dermatology</i> , 1992, 98, 343-350.	0.3	110
683	Short-Term Retinoic Acid Treatment Increases In Vivo, but Decreases In Vitro, Epidermal Transglutaminase-K Enzyme Activity and Immunoreactivity. <i>Journal of Investigative Dermatology</i> , 1992, 99, 283-288.	0.3	29
684	Expression of Growth Hormone Receptor, Insulin-Like Growth Factor 1 (IGF-1) and IGF-1 Receptor mRNA and Proteins in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 99, 343-349.	0.3	181

#	ARTICLE	IF	CITATIONS
685	Cellular Localization of mRNA for Cellular Retinoic Acidâ€‘Binding Protein II and Nuclear Retinoic Acid Receptor-Î³1 in Retinoic Acidâ€‘Treated Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 99, 146-150.	0.3	37
686	Mechanisms of action of retinoic acid in skin repair. <i>British Journal of Dermatology</i> , 1992, 127, 21-24.	1.4	8
687	The clinical identification and quantification of photodamage. <i>British Journal of Dermatology</i> , 1992, 127, 37-42.	1.4	96
688	Differential Regulation of Retinoic Acid Receptors and Binding Proteins in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 98, 673-679.	0.3	105
689	A photonumeric scale for the assessment of cutaneous photodamage. <i>Archives of Dermatology</i> , 1992, 128, 347-351.	1.7	131
690	Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. <i>Archives of Dermatology</i> , 1992, 128, 786-790.	1.7	29
691	Treatment of pyoderma gangrenosum with cyclosporine. <i>Archives of Dermatology</i> , 1992, 128, 1060-1064.	1.7	135
692	A photonumeric scale for the assessment of cutaneous photodamage. <i>Archives of Dermatology</i> , 1992, 128, 1406-1407.	1.7	0
693	Keratinocytes as initiators of inflammation. <i>Lancet, The</i> , 1991, 337, 211-214.	6.3	724
694	A Review and Update of the Clinical Uses of Cyclosporine in Dermatology. <i>Dermatologic Clinics</i> , 1991, 9, 805-817.	1.0	31
695	Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-Î±) in allergic contact dermatitis (rhus dermatitis). <i>British Journal of Dermatology</i> , 1991, 124, 519-526.	1.4	158
696	Aberrant Intercellular Adhesion Molecule-1 (ICAM-1) Expression by Hair-Follicle Epithelial Cells and Endothelial Leukocyte Adhesion Molecule-1 (ELAM-1) by Vascular Cells Are Important Adhesion-Molecule Alterations in Alopecia Areata. <i>Journal of Investigative Dermatology</i> , 1991, 96, S91-S92.	0.3	37
697	Induction of Proliferation of Growth-Inhibited Keratinocytes and Fibroblasts in Monolayer Culture by Sodium Lauryl Sulfate: Comparison with All-Trans Retinoic Acid. <i>Journal of Investigative Dermatology</i> , 1991, 97, 917-921.	0.3	30
698	Differential modulation of keratinocyte intercellular adhesion molecule-i expression by gamma interferon and phorbol ester: evidence for involvement of protein kinase C signal transduction. <i>British Journal of Dermatology</i> , 1990, 122, 333-342.	1.4	82
699	Not all spindled-shaped cells embedded in a collagenous stroma are fibroblasts: recognition of the "collagen-associated dendrophage". <i>Journal of Cutaneous Pathology</i> , 1990, 17, 252-253.	0.7	21
700	Phosphoinositide-Mediated Signal Transduction in Normal and Psoriatic Epidermis. <i>Journal of Investigative Dermatology</i> , 1990, 95, S15-S17.	0.3	18
701	Lymphocyte Trafficking in Psoriasis: A New Perspective Emphasizing the Dermal Dendrocyte with Active Dermal Recruitment Mediated Via Endothelial Cells Followed by Intra-Epidermal T-Cell Activation. <i>Journal of Investigative Dermatology</i> , 1990, 95, S35-S37.	0.3	50
702	Cyclophilin Content of Normal and Psoriatic Epidermis. <i>Journal of Investigative Dermatology</i> , 1990, 94, 436-440.	0.3	11

#	ARTICLE	IF	CITATIONS
703	Abnormal Cutaneous Topobiology: The Molecular Basis for Dermatopathologic Mononuclear Cell Patterns in Inflammatory Skin Disease. <i>Journal of Investigative Dermatology</i> , 1990, 95, S128-S131.	0.3	20
704	The Role of Adhesion Molecules, Chemotactic Factors, and Cytokines in Inflammatory and Neoplastic Skin Disease—1990 Update. <i>Journal of Investigative Dermatology</i> , 1990, 94, s151-s157.	0.3	199
705	Systemic and local administration of cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1242-1247.	0.6	26
706	Oral cyclosporine for the treatment of alopecia areata. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 242-250.	0.6	186
707	Constitutive absence and interferon- γ -induced expression of adhesion molecules in basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 721-726.	0.6	26
708	Intralesional cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 94-100.	0.6	98
709	Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. <i>New England Journal of Medicine</i> , 1990, 323, 290-294.	13.9	196
710	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. <i>Archives of Dermatology</i> , 1990, 126, 339-350.	1.7	146
711	Sulfasalazine improves psoriasis. A double-blind analysis. <i>Archives of Dermatology</i> , 1990, 126, 487-493.	1.7	62
712	Gamma interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-1 (ICAM-1) antigens. <i>British Journal of Dermatology</i> , 1989, 120, 1-7.	1.4	102
713	Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. <i>British Journal of Dermatology</i> , 1989, 121, 421-431.	1.4	354
714	Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. <i>Journal of the American Academy of Dermatology</i> , 1989, 20, 617-629.	0.6	494
715	Long-term cyclosporin for psoriasis. <i>British Journal of Dermatology</i> , 1989, 120, 253-260.	1.4	75
716	(25) Long-term follow-up of low-dose cyclosporin treatment for psoriasis. <i>British Journal of Dermatology</i> , 1988, 119, 56-57.	1.4	0
717	Cyclosporin A does not Inhibit Epidermal Growth at Therapeutic Levels. <i>Journal of Investigative Dermatology</i> , 1988, 90, 536.	0.3	0
718	TOPICAL CYCLOSPORIN AND PSORIASIS. <i>Lancet</i> , The, 1987, 329, 806.	6.3	54
719	Cladins bind to reticulin in a lectin-like manner. <i>Archives of Dermatological Research</i> , 1987, 279, 232-235.	1.1	16
720	The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. <i>British Journal of Dermatology</i> , 1987, 116, 503-510.	1.4	145

#	ARTICLE	IF	CITATIONS
721	Exacerbation of psoriasis by indomethacin. British Journal of Dermatology, 1987, 117, 799-800.	1.4	39
722	(8) Comparison of psoriasis treated with cyclosporin alone or cyclosporin and clobetasol propionate. British Journal of Dermatology, 1987, 117, 35-36.	1.4	5
723	(11) Oesophageal strictures in cicatricial pemphigoid. British Journal of Dermatology, 1987, 117, 37-37.	1.4	1
724	PSORIASIS AND INTERFERON. Lancet, The, 1986, 328, 342-343.	6.3	6
725	Psoriasis. BMJ: British Medical Journal, 1986, 293, 266-266.	2.4	2
726	IgA anti-endomysial antibody detection in the serum of patients with dermatitis herpetiformis following gluten challenge. Archives of Dermatological Research, 1985, 277, 349-351.	1.1	25
727	The Effects of Topical Treatment with Steroids or Dithranol on Epidermal T Lymphocytes and Dendritic Cells in Psoriasis. Scandinavian Journal of Immunology, 1985, 22, 471-477.	1.3	35
728	Photoaging. , 0, , 326-336.		0